ClinicalTrials.gg
RecruitingNCT07522151Updated May 13, 2026

Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

A Phase 3 interventional study of Adebrelimab plus S-1 and oxaliplatin and Adebrelimab blank preparation plus S-1 and oxaliplatin. in Locally Advanced Gastric or Gastroesophageal Junction Cancer, sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
874
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two combination regimens.

02

Conditions studied

  • Locally Advanced Gastric or Gastroesophageal Junction Cancer
03

In context

Lead sponsor

Shanghai Shengdi Pharmaceutical Co., Ltd is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with confirmed gastric cancer or gastroesophageal junction cancer.
  2. Age: ≥18 years old, \<75 years old, both male and female are eligible.
  3. Before entering the study, the investigator has evaluated and determined that the subject is suitable and plans to undergo therapy + radical surgery for curative purposes.
  4. Gastric cancer or gastroesophageal junction cancer applicable to the 8th edition of the AJCC gastric cancer staging criteria.
  5. Fresh specimens (preferred) or formalin-fixed, paraffin-embedded tumor tissue blocks or unstained tumor specimen sections obtained within 6 months before randomization can be provided.
  6. (ECOG) performance status score of 0 - 1.
  7. Expected survival ≥ 6 months.
  8. Adequate organ and bone marrow function.
  9. Female subjects are either infertile or fertile, with a negative serum pregnancy test result within 3 days before the start of study medication and not in the lactation period. Fertile female subjects and male subjects whose partners are fertile must agree to avoid sperm/egg donation from the time of signing the form until 6 months after the last administration of the drug, and comply with relevant requirements.
  10. Consent has been obtained from the individual and the informed consent form has been signed, willing and able to comply with planned visits, study treatment, laboratory tests, and other trial procedures.

Exclusion criteria

Exclusion Criteria:

  1. Gastric cancer known to be squamous cell carcinoma, undifferentiated carcinoma or other histological types, or adenocarcinoma mixed with other histological types.
  2. Gastric esophageal junction cancer, Siewert type I; or Siewert type II with esophageal invasion length ≥ 4 cm; or other cases not suitable for clinical staging assessment using the 8th edition of the AJCC gastric cancer staging criteria, or not suitable for conventional surgical methods or approaches for gastric cancer.
  3. The subject's weight has decreased by more than 20% within 2 months before randomization.
  4. Previous anti-tumor treatment for gastric cancer/gastric esophageal junction cancer (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy or tumor embolization).
  5. Known allergy to any component of the drug (including adibelimab/placebo, tegafur, and oxaliplatin), or allergy to humanized monoclonal antibody products.
  6. Diagnosis of any other malignant tumor within 5 years before entering the study, except for locally treatable and cured skin basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma.
  7. History of immunodeficiency (including positive test, other acquired or congenital immunodeficiency diseases) or organ transplantation (including allogeneic organ transplantation or hematopoietic stem cell transplantation, etc.); history of active disease, except for immune disorders that do not require systemic treatment (such as vitiligo, psoriasis, etc.) or autoimmune diseases that can be improved through hormone replacement therapy (such as type 1 diabetes or hypothyroidism).
  8. Severe, unhealed or open wounds, active ulcers, or untreated fractures.
  9. Active severe digestive system diseases.
  10. Presence of interstitial pneumonia or interstitial lung disease.
  11. Severe cardiovascular or metabolic diseases.
  12. Active or infection (HBsAg positive and viral copy number ≥ 2000 IU/mL, HCV antibody positive and HCV RNA above the at the research center), or co-infection with hepatitis B and hepatitis C.
  13. Active tuberculosis infection within 1 year before randomization (including but not limited to pulmonary tuberculosis, intestinal tuberculosis, etc.), or a history of active tuberculosis infection more than 1 year ago but without regular treatment.
  14. Severe infection within 4 weeks before randomization.
  15. Known history of abuse of psychotropic drugs or drug addiction.
  16. Presence of other serious physical or mental diseases or abnormal laboratory tests that may increase the risk of participation in the study, or interfere with the study results, and patients considered unsuitable for participation in the study by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
874 participants (estimated)

Study arms

  • Experimental
    Treatment group A: Adebrelimab with SOX.

    Drug: Adebrelimab plus S-1 and oxaliplatin

  • Experimental
    Treatment group B: placebo with SOX.

    Drug: Adebrelimab blank preparation plus S-1 and oxaliplatin.

Interventions

  • DrugAdebrelimab plus S-1 and oxaliplatin

    Drug pages: Adebrelimab · Tegafur · Gimeracil · Oxonic Acid · Oxaliplatin

    Adebrelimab plus S-1 and oxaliplatin

  • DrugAdebrelimab blank preparation plus S-1 and oxaliplatin.

    Adebrelimab blank preparation plus S-1 and oxaliplatin.

06

What researchers measure

Primary outcomes

  1. Investigator-assessed EFS

    Assessments BY INVESTIGATORS

    Time frame: About 8 years

Secondary outcomes

  1. Complete response (pCR) rate as assessed by the Pathology Review Committee (PRC)

    Complete remission (pCR) rates after surgery

    Time frame: About 3 years

  2. Rate of pathologically significant response (MPR) as assessed by the Pathology Review Committee (PRC)

    Pathologically significant response (MPR) rate after surgery

    Time frame: About 3 years

  3. EFS as assessed by an independent review committee (IRC)

    Independent Review Committee (IRC) evaluation

    Time frame: About 8 years

  4. DFS, as assessed by investigator /IRC

    Investigator /IRC assessment

    Time frame: About 8 years

  5. pCR rate by central pathological evaluation

    Central pathological evaluation was studied

    Time frame: About 3 years

  6. R0 resection rate of neoadjuvant therapy evaluated by investigators in different treatment groups

    Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator

    Time frame: About 8 years

  7. D2 radical resection rate of neoadjuvant therapy evaluated by investigators in different treatment groups

    Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator

    Time frame: About 8 years

  8. objective response rate (ORR) of neoadjuvant therapy evaluated by investigators in different treatment groups

    Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator

    Time frame: About 8 years

  9. The incidence of adverse events (AE) were evaluated according to NCI-CTCAE 6.0

    NCI-CTCAE 6.0 was used for evaluation

    Time frame: About 4 years

  10. The severity of serious adverse events (SAE) were evaluated according to NCI-CTCAE 6.0

    NCI-CTCAE 6.0 was used for evaluation

    Time frame: About 4 years

07

Study locations

1 of 1 sites recruiting
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 10000, China
    Recruiting
    • Jiafu Ji · Principal investigator
    • Lin Shen · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Dec 2029, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2026
First posted
Apr 13, 2026
StartActual
May 7, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Feb 2034
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07522151
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
May 7, 2026
Primary completion
Dec 2029 (estimated)
Completion
Feb 2034 (estimated)
Last update
May 13, 2026

Study contacts

Bin Bai
Contact
bin.bai@hengrui.com
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adebrelimab · Tegafur · Gimeracil · Oxonic Acid · Oxaliplatin

Start the discussion